These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

209 related articles for article (PubMed ID: 9934342)

  • 1. Effect of initial drug choice on persistence with antihypertensive therapy: the importance of actual practice data.
    Caro JJ; Speckman JL; Salas M; Raggio G; Jackson JD
    CMAJ; 1999 Jan; 160(1):41-6. PubMed ID: 9934342
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Persistence with treatment for hypertension in actual practice.
    Caro JJ; Salas M; Speckman JL; Raggio G; Jackson JD
    CMAJ; 1999 Jan; 160(1):31-7. PubMed ID: 9934341
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Stepped care for hypertension: are the assumptions valid?
    Caro JJ
    J Hypertens Suppl; 1997 Dec; 15(7):S35-9. PubMed ID: 9532519
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Antihypertensive persistence and drug class.
    Marentette MA; Gerth WC; Billings DK; Zarnke KB
    Can J Cardiol; 2002 Jun; 18(6):649-56. PubMed ID: 12107422
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Persistence with treatment in newly treated middle-aged patients with essential hypertension.
    Perreault S; Lamarre D; Blais L; Dragomir A; Berbiche D; Lalonde L; Laurier C; St-Maurice F; Collin J
    Ann Pharmacother; 2005 Sep; 39(9):1401-8. PubMed ID: 16076920
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Long-term persistence with antihypertensive drugs in new patients.
    Degli Esposti E; Sturani A; Di Martino M; Falasca P; Novi MV; Baio G; Buda S; Volpe M
    J Hum Hypertens; 2002 Jun; 16(6):439-44. PubMed ID: 12037702
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Shifting trends in the pharmacologic treatment of hypertension in a Nigerian tertiary hospital: a real-world evaluation of the efficacy, safety, rationality and pharmaco-economics of old and newer antihypertensive drugs.
    Adigun AQ; Ishola DA; Akintomide AO; Ajayi AA
    J Hum Hypertens; 2003 Apr; 17(4):277-85. PubMed ID: 12714973
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Antihypertensive drug persistence and compliance among newly treated elderly hypertensives in ontario.
    Friedman O; McAlister FA; Yun L; Campbell NR; Tu K;
    Am J Med; 2010 Feb; 123(2):173-81. PubMed ID: 20103027
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Existing treatment strategies: does noncompliance make a difference?
    Caro JJ; Speckman JL
    J Hypertens Suppl; 1998 Sep; 16(7):S31-4. PubMed ID: 9855029
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A comparison between persistence to therapy in ALLHAT and in everyday clinical practice: a generalizability issue.
    Cardinal H; Monfared AA; Dorais M; LeLorier J
    Can J Cardiol; 2004 Mar; 20(4):417-21. PubMed ID: 15057318
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Persistence and discontinuation patterns of antihypertensive therapy among newly treated patients: a population-based study.
    Bourgault C; Sénécal M; Brisson M; Marentette MA; Grégoire JP
    J Hum Hypertens; 2005 Aug; 19(8):607-13. PubMed ID: 15920457
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Choice of initial antihypertensive medication and continuation of use.
    Grégoire JP
    Can J Cardiol; 1999 Nov; 15 Suppl F():39F-41F. PubMed ID: 10579751
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Antihypertensive drug prescription trends at the primary health care centres in Bahrain.
    Jassim al Khaja KA; Sequeira RP; Wahab AW; Mathur VS
    Pharmacoepidemiol Drug Saf; 2001 May; 10(3):219-27. PubMed ID: 11501335
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Medication adherence before an increase in antihypertensive therapy: a cohort study using pharmacy claims data.
    Grant RW; Singer DE; Meigs JB
    Clin Ther; 2005 Jun; 27(6):773-81. PubMed ID: 16117984
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The 2004 Canadian recommendations for the management of hypertension: Part II--Therapy.
    Khan NA; McAlister FA; Campbell NR; Feldman RD; Rabkin S; Mahon J; Lewanczuk R; Zarnke KB; Hemmelgarn B; Lebel M; Levine M; Herbert C;
    Can J Cardiol; 2004 Jan; 20(1):41-54. PubMed ID: 14968142
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Current recommendations for the treatment of hypertension: are they still valid?
    Moser M
    J Hypertens Suppl; 2002 Feb; 20(1):S3-10. PubMed ID: 11996197
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Copayment level and compliance with antihypertensive medication: analysis and policy implications for managed care.
    Taira DA; Wong KS; Frech-Tamas F; Chung RS
    Am J Manag Care; 2006 Nov; 12(11):678-83. PubMed ID: 17090224
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Uptake of angiotensin II receptor blockers in the treatment of hypertension.
    Greving JP; Denig P; van der Veen WJ; Beltman FW; Sturkenboom MC; de Zeeuw D; Haaijer-Ruskamp FM
    Eur J Clin Pharmacol; 2005 Jul; 61(5-6):461-6. PubMed ID: 15912393
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The need for evidence in hypertension management: historical perspective.
    Moawad MA
    Ann Saudi Med; 2005; 25(5):367-74. PubMed ID: 16270757
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Influence of physicians' management and communication ability on patients' persistence with antihypertensive medication.
    Tamblyn R; Abrahamowicz M; Dauphinee D; Wenghofer E; Jacques A; Klass D; Smee S; Eguale T; Winslade N; Girard N; Bartman I; Buckeridge DL; Hanley JA
    Arch Intern Med; 2010 Jun; 170(12):1064-72. PubMed ID: 20585073
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.